Inversago Pharma, a pioneering biotech company, specializes in developing transformative therapies for metabolic and fibrotic diseases. Based in Montreal, Canada, Inversago Pharma leads the industry with its focus on peripherally acting CB1 receptor (CB1r) blocker therapies. Their flagship program, INV-202, targets metabolic disorders and is currently undergoing evaluation in Phase 2 studies for patients with diabetic kidney disease and obesity.

Inversago's pipeline includes innovative treatments for complications of diabetes, obesity, and fibrotic diseases like pulmonary fibrosis and systemic sclerosis. By regulating peripheral CB1 receptors, Inversago aims to provide safe and potent inhibitors to address the root causes of metabolic disorders. With a commitment to advancing peripherally acting CB1r blockers, Inversago Pharma is dedicated to improving the lives of patients facing these challenging conditions